Trial Profile
Efficacy and safety of escitalopram in the treatment of depressive patients with acute coronary artery syndrome: a double-blind placebo-controlled trial
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 07 Jan 2022
Price :
$35
*
At a glance
- Drugs Escitalopram (Primary)
- Indications Depressive disorders
- Focus Adverse reactions; Therapeutic Use
- Acronyms EsDEPACS
- 09 Oct 2018 Results presented at the 31st Annual Congress of the European College of Neuropsychopharmacology
- 24 Jul 2018 Results published in the JAMA: the Journal of the American Medical Association
- 25 Aug 2011 New source identified and integrated (Korean Clinical Trials Register KCT0000053)